A new blood test for diagnosing Alzheimer’s disease has been approved by the U.S. Food & Drug Administration [FDA].  The Lumipulse test is 90% accurate and works by detecting a tau protein which can indicate the presence of amyloid plaques in the brain, considered the hallmark of Alzheimer’s disease. 

 The test is still being refined and doesn’t diagnose Alzheimer’s disease on its own. The Lumipulse test is meant to be part of an evaluation for Alzheimer’s disease, including physical and medical history and imaging scans of the brain.

Previous tests required a lumbar puncture to look for the tau protein in cerebrospinal fluid which can be expensive and invasive.  

The test is currently recommended only for people who show symptoms of Alzheimer’s and is so new, many healthcare professionals may not know about it.  In that case, the patient should ask for a referral to a neurologist or memory specialist.  Insurance coverage may vary with different plans but is expected to be covered soon as it is less expensive than previous tests.

The advantage of early diagnosis allows patients to begin to consider next steps such as treatment options and clinical trials.  In addition, lifestyle changes can be considered -physical activity, healthy diet, quality sleep, stress management, social connections, and mental stimulation – which are known to slow the development of Alzheimer’s disease.  

*********** 

For more information on the Lumipulse test, click here https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/in-depth/new-blood-tests-alzheimers/art-20585060

For information on keeping your brain healthy, click here.

This article is submitted by Dementia Friendly Community Initiative, a program of Whitewater Seniors in the Park to help educate the community about dementia and to support patients and their care partners.  New committee members are very welcome!  Contact jfrench@whitewater-wi.gov or call Jennifer at 262 473 0535       https://www.whitewater-wi.gov/273/Seniors-In-the-Park